Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00262990
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2005-12-06
Brief Title:
Patupilone Versus Doxorubicin in Patients With Ovarian Primary Fallopian or Peritoneal Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Randomized Parallel Group Open-label Active Controlled Multicenter Phase III Trial of Patupilone EPO906 Versus Pegylated Liposomal Doxorubicin in TaxanePlatinum RefractoryResistant Patients With Recurrent Epithelial Ovarian Primary Fallopian or Primary Peritoneal Cancer
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin Additionally this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian primary fallopian or primary peritoneal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None